Italy is the first country in the world for cultural, historical and monumental heritage. The use of traditional biocides to reduce bio-deterioration phenomena of monuments is increasingly deterred, due to risks for human health and environment, as well as for potential interference with materials.

We have synthesized molecules with high antimicrobial activity against bacteria isolated from cultural heritage, trapped them into biocompatible, non-polluting, non-toxic, biodegradable membranes, to applied in situ in order to give “new life” to cultural heritage. This bio-cleaning treatment does not lead any damage for artworks or risks to environment and the operators.

Today, good nutrition is an important part of leading a healthy lifestyle.

We want to improve or enrich the nutritional values of local biological products, to valorize our region, using substances with well known beneficial properties.

For us is important to increase the beneficial effect on health of different consumer groups, when consume this products. Enhancing the substances bioavailability, without altering the features, introduces benefits on the health and well-being of the population, to promote optimal health for different consumer groups with positive effects on economic and social factors.

We have selected different substances, and we are starting the procedure for their inclusion in the list of Directive 2002/46/EC on food supplements.

We have carried out a little sensory evaluation of a bio local EVOO with three different selected beneficial compounds, and evaluated the appearance, aroma, flavor and texture of each sample. No significant changes were reported compared with control.

Currently, cancer therapies related to TNc lack effective, low-toxicity and/or invasive solutions. The company business idea is based on the current need to discover and develop innovative therapeutic molecules for the treatment of solid tumors, especially of TNc.

TNcKILLERS is developing and validating innovative drug delivery systems (DDS), able to trap synthetic therapeutic molecules, and deliver them in loco, acting selectively and without side effects. These innovative systems can to become a valid alternative for treatment of solid tumors for which surgical removal of the tissue/organ involved would be the only viable alternative.

The molecules, referable to two international patents (PCT), incorporated in biocompatibles, bio-absorbables and non-toxic, controlled DDS, directly applied to the tumor mass. The new mwthods developed by company, with enhancing the active principle bioavailability, organ selectivity without systemic toxicity, aim also to overcome mastectomies (both partial and total) where possible, leading a positive psychological effect on young patients (<45 years) and their social relationships.

Preliminary data are promising, molecules show a high cytotoxic activity on solid tumor cell lines, with an efficiency at low concentrations and a relatively negligible toxicity profile; these data are supported by experimental evidence in vitro and in vivo. It was observed a low systemic and cardiac toxicity as compared with drug currently used, an inhibition of cancer growth in vivo and in metastatic models and, the application of drug delivery system in vivo shown a human tumor mass reduction in just twelve days.